We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Richmond, Va.-based Indivior, maker of the opioid treatment Suboxone (buprenorphine-naloxone), has announced plans to purchase Opiant Pharmaceuticals, a Santa Monica, Calif., producer of the opioid overdose nasal spray Narcan (naloxone), in a deal valued at $145 million. Read More
Richmond, Va.-based Indivior, maker of the opioid treatment Suboxone (buprenorphine-naloxone), has announced plans to purchase Opiant Pharmaceuticals, a Santa Monica, Calif., producer of the opioid overdose nasal spray Narcan (naloxone), in a deal valued at $145 million. Read More
AbbVie has filed a complaint against several generics producers — including Teva Pharmaceuticals and Novartis’ Sandoz unit — alleging the companies infringed on patents for its endometriosis drug Orilissa (elagolix) by planning to make generic alternatives. Read More
Takeda, Zedira and Dr. Falk Pharma inked a collaboration and licensing agreement to develop TAK-227, an investigational therapy for patients with celiac disease, an autoimmune disorder characterized by inability to tolerate gluten. The therapy currently is undergoing a phase 2b trial. Read More
Eli Lilly plans to further expand into gene therapies with the $487 million purchase of Massachusetts-based biotech Akouos, a company developing gene treatments for hearing loss. Read More